The reiteration of an Overweight rating by Cantor Fitzgerald indicates their positive outlook on Humacyte. However, as the price target is maintained at $6, it suggests that the analyst does not foresee significant short-term price movement. Therefore, the impact on the stock price is neutral in the short term.